|Bid||346.00 x N/A|
|Ask||362.00 x N/A|
|Day's range||351.10 - 359.45|
|52-week range||14.90 - 374.70|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Atea (AVIR) is developing an oral drug candidate, AT-527, as a potential treatment for COVID-19 in outpatients as well as hospitalized settings in several studies.
Roche (RHHBY) posts an encouraging performance in the third quarter and the first nine months of 2021 driven by demand for coronavirus tests due to the Delta variant and recovery in pharma sales.
Severin Schwan, chief executive officer at Roche Holding AG, discusses third-quarter earnings, the demand for Covid-19 tests and the company���s M&A strategy. Roche���s third-quarter revenue climbed 8.7% to $17.3 billion. He speaks on ���Bloomberg Markets: European Open.��� (Source: Bloomberg)